Comparative Pharmacology
Head-to-head clinical analysis: METHOCARBAMOL AND ASPIRIN versus SOMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOCARBAMOL AND ASPIRIN versus SOMA.
METHOCARBAMOL AND ASPIRIN vs SOMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is unknown but may involve general CNS depression. Aspirin irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Centrally acting muscle relaxant; acts at brainstem reticular formation and spinal cord levels to inhibit polysynaptic reflexes, possibly via GABAergic and monoaminergic pathways.
1 to 2 tablets (methocarbamol 400 mg / aspirin 325 mg per tablet) orally every 4-6 hours as needed, not to exceed 6 tablets per day.
250 mg to 350 mg orally three times daily and at bedtime.
None Documented
None Documented
Clinical Note
moderateSomatostatin + Cyclosporine
"The serum concentration of Cyclosporine can be decreased when it is combined with Somatostatin."
Clinical Note
moderateSomatostatin + Methylphenobarbital
"The risk or severity of adverse effects can be increased when Somatostatin is combined with Methylphenobarbital."
Clinical Note
moderateSomatostatin + Hexobarbital
"The risk or severity of adverse effects can be increased when Somatostatin is combined with Hexobarbital."
Clinical Note
moderateMethocarbamol: 1–2 hours (terminal). Aspirin: 15–20 minutes for parent drug; salicylic acid: 2–3 hours (low doses) to 15–30 hours (high doses, due to saturable metabolism). Combined product: consider aspirin's longer terminal half-life at therapeutic doses.
1-2 hours; prolonged to 3-4 hours in hepatic impairment; parent drug rapidly cleared via CYP2C19 metabolism to meprobamate (active, t1/2 6-16 hours).
Methocarbamol: Renal excretion of glucuronide and sulfate conjugates (95%) with <5% unchanged. Aspirin: Renal excretion of salicylic acid and metabolites (primarily salicyluric acid and glucuronides) with ~50% as salicylate at alkaline pH; biliary elimination <5%.
Renal: ~60-70% as metabolites (including meprobamate and glucuronide conjugates); fecal: minimal; biliary: negligible.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
Somatostatin + Thiamylal
"The risk or severity of adverse effects can be increased when Somatostatin is combined with Thiamylal."